Abstract
Herein we report the use of next generation maleimides (NGMs) for the construction of a potent antibody-drug conjugate (ADC) via functional disulfide bridging. The linker has excellent stability in blood serum and the ADC, armed with monomethyl auristatin E (MMAE), shows excellent potency and cancer cell selectivity in vitro.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Monoclonal / chemistry*
-
Cell Proliferation / drug effects
-
Click Chemistry
-
Disulfides / chemistry*
-
Fluorescent Dyes / chemistry
-
Humans
-
Immunoconjugates / chemistry*
-
Immunoconjugates / toxicity
-
MCF-7 Cells
-
Oligopeptides / chemistry*
-
Trastuzumab / chemistry
Substances
-
Antibodies, Monoclonal
-
Disulfides
-
Fluorescent Dyes
-
Immunoconjugates
-
Oligopeptides
-
Trastuzumab
-
monomethyl auristatin E